Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human TFAP2A Antibodies:
anti-Mouse (Murine) TFAP2A Antibodies:
anti-Rat (Rattus) TFAP2A Antibodies:
Go to our pre-filtered search.
Human Polyclonal TFAP2A Primary Antibody for WB - ABIN3434032
Mitchell, Abdelrahim, Weng, Stafford, Safe, Bar-Eli, Liu: Regulation of KiSS-1 metastasis suppressor gene expression in breast cancer cells by direct interaction of transcription factors activator protein-2alpha and specificity protein-1. in The Journal of biological chemistry 2006
Show all 4 Pubmed References
Mouse (Murine) Polyclonal TFAP2A Primary Antibody for WB - ABIN1945094
Moser, Pscherer, Bauer, Imhof, Seegers, Kerscher, Buettner: The complete murine cDNA sequence of the transcription factor AP-2. in Nucleic acids research 1993
Show all 5 Pubmed References
Human Polyclonal TFAP2A Primary Antibody for WB - ABIN1882156
Semenza: Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. in The Biochemical journal 2007
Show all 3 Pubmed References
Chicken Monoclonal TFAP2A Primary Antibody for ICC, IF - ABIN261468
Milgrom-Hoffman, Michailovici, Ferrara, Zelzer, Tzahor: Endothelial cells regulate neural crest and second heart field morphogenesis. in Biology open 2014
Show all 2 Pubmed References
our results indicate that AP-2alpha can reverse the Multidrug resistance (MDR) of gastric cancer cells, which may be realized by inhibiting the Notch (show NOTCH1 Antibodies) signaling pathway.
High-confidence AP2alpha (show AP2A1 Antibodies)-binding peaks were detected in the regulatory regions of many target genes involved in the development of facial tissues including MSX1 (show MSX1 Antibodies), IRF6 (show IRF6 Antibodies), TBX22 (show TBX22 Antibodies), and MAFB (show MAFB Antibodies). In addition, we uncovered multiple single-nucleotide polymorphisms (SNPs) disrupting a conserved AP2alpha (show AP2A1 Antibodies) consensus sequence.
We identified two SLN (show SLN Antibodies) genes (PIGR (show PIGR Antibodies) and TFAP2A) that provided high prognostic accuracy in SLN (show SLN Antibodies)-positive melanoma patients (AUC = 0.864). These two SLN (show SLN Antibodies) genes, along with clinicopathological features, can differentiate the high- and low-risk groups in node-positive melanoma patients
We identified miR (show MLXIP Antibodies)-1254 as a negative regulator inhibiting HO-1 (show HMOX1 Antibodies) translation by directly targeting HO-1 (show HMOX1 Antibodies) 3'UTR (show UTS2R Antibodies) via its seed region, and suppressing HO-1 (show HMOX1 Antibodies) transcription via non-seed region-dependent inhibition of transcriptional factor AP-2 alpha (TFAP2A), a transcriptional activator of HO-1 (show HMOX1 Antibodies).
dimerization-defective mutant of Nef failed to interact with either CD4 (show CD4 Antibodies) or AP-2 (show GTF3A Antibodies) in the BiFC assay, indicating that Nef quaternary structure is required for CD4 (show CD4 Antibodies) and AP-2 (show GTF3A Antibodies) recruitment as well as CD4 (show CD4 Antibodies) down-regulation
Data show that TFAP2A binds many of the same regulatory elements as MITF (show MITF Antibodies) in melanocytes.
the atrial fibrillation (AF)-associated SNP rs2595104 altered PITX2c (show PITX2 Antibodies) expression via interaction with TFAP2a; such a pathway could ultimately contribute to AF susceptibility at the PITX2 (show PITX2 Antibodies) locus associated with AF
AP-2a is an important transcription factor of DEK (show DEK Antibodies) expression, which is correlated with the methylation level of the DEK (show DEK Antibodies) core promoter in hepatocellular carcinoma .
AP-2alpha expression has a role in human hepatocellular cancer by regulating signaling to affect cell growth and migration
Hepatitis B virus X protein is able to elevate the expression of SPHK1 (show SPHK1 Antibodies) in hepatoma cells by upregulating transcription factor AP2 alpha.
Genetic interaction between tfap2a and mitfa suggest that the factors en (show MITF Antibodies)coded by these genes regulate shared targets in melanocytes, possibly within single or converging pathways.
these data support a model in which Tfap2a, acting through Bmp7a (show BMP7 Antibodies), modulates Fgf and Notch (show NOTCH1 Antibodies) signaling to control the duration, amount and speed of SAG (show SAG Antibodies) neural development.
Prdm1a (show PRDM1 Antibodies) directly binds and activates a tfap2a enhancer at the NPB (show NPB Antibodies)
Low Bmp activates expression of the transcription factor Tfap2a as part of a gene regulatory network that coordinates development of neural crest, preplacodal ectoderm and individual placodes in zebrafish.
tfap2a and foxd3 (show FOXD3 Antibodies) are expressed during gastrulation prior to neural crest induction in distinct, complementary, domains; tfap2a is expressed in the ventral non-neural ectoderm and foxd3 (show FOXD3 Antibodies) in the dorsal mesendoderm and ectoderm
These results reveal that mutations in TFAP2A are associated with a wide range of eye phenotypes and that hypomorphic tfap2a mutations can increase the risk of developmental defects arising from mutations at other loci.
These findings reveal that Tfap2 activity, mediated redundantly by Tfap2a and Tfap2e (show TFAP2E Antibodies), promotes melanophore differentiation in parallel with Mitf (show MITF Antibodies) by an effector other than Kit.
Results demonstrate that tfap2a is required for early steps in neural crest development and for the survival of a subset of neural crest derivatives.
data show that hindbrain noradrenergic neurons of the locus coeruleus and the posterior groups both require Tfap2a to establish their noradrenergic identity
Ap-2alpha regulates multiple steps of melanophore development, and is required for development of other neuronal and non-neuronal neural crest derivatives.
AP2a initiates neural border patterning and is sufficient to elicit a neural border-like pattern in neuralized (show NEURL Antibodies) ectoderm.
RNA interference of transcriptional factor activator protein 2alpha (AP-2alpha) reversed the inhibitory effects of aspirin on atherosclerosis in Apoe (show APOE Antibodies)-/- mice.
Study systematically examined the expression profile of AP-2 family in the developing mouse and chick spinal cord and found that AP-2alpha and AP-2beta (show TFAP2B Antibodies) are specifically expressed in post-mitotic dorsal interneurons. Subsequent functional assessment in chick embryos demonstrated that AP-2alpha and AP-2beta (show TFAP2B Antibodies) have distinct functions in dorsal interneuron specification and differentiation.
MEX3C (show MEX3C Antibodies) associates with the endolysosomal compartment through an endocytosis-like process. siRNA-mediated inhibition of the MEX3C (show MEX3C Antibodies) or AP-2 complex (show AP2B1 Antibodies) substantially decreased exosomal but not cellular microRNA miR (show MLXIP Antibodies)-451a expression
High AP-2 alpha phosphorylation is associated with abdominal aortic aneurysm.
overexpression of Dnmt3a (show DNMT3A Antibodies) partially rescued the impairment of adipogenesis induced by AP2alpha knockdown.
TFAP2A is a conserved component of the core network that regulates EMT (show ITK Antibodies), acting as a repressor of many genes, including ZEB2 (show ZEB2 Antibodies).
The AP-2beta (show TFAP2B Antibodies) transcription factor is an important effector of PITX2 (show PITX2 Antibodies) function during corneal development, required for differentiation of corneal endothelium and establishment of angiogenic privilege.
the regulation of synaptic-vesicle (SV) recycling via early endosomes by the interdependent regulation of AP-2-mediated endocytosis and AP-1 (show JUN Antibodies)/sigma1B (show AP1S2 Antibodies)-mediated SV reformation, is reported.
By gain-of function and loss-of-function approaches, ap2a and 2b were identified to be the major downstream targets of Ptf1a (show PTF1A Antibodies) to specify the amacrine cell fate.
The protein encoded by this gene is a transcription factor that binds the consensus sequence 5'-GCCNNNGGC-3'. The encoded protein functions as either a homodimer or as a heterodimer with similar family members. This protein activates the transcription of some genes while inhibiting the transcription of others. Defects in this gene are a cause of branchiooculofacial syndrome (BOFS). Three transcript variants encoding different isoforms have been found for this gene.
transcription factor AP-2 alpha
, transcription factor AP-2
, AP-2 transcription factor
, activating enhancer-binding protein 2-alpha
, activator protein 2
, transcription factor AP-2-alpha
, transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha)
, mont blanc
, activating enhancer-binding protein 2 alpha
, Transcription factor AP-2 alpha
, AP-2 alpha
, Ap-2 (a)